F-1/A: Nasus Pharma Launches IPO Amidst Going Concern Warning

Nasus Pharma Ltd., a clinical-stage pharmaceutical company, is launching an initial public offering of 1,250,000 ordinary shares, seeking to raise approximately $9.5 million to advance its intranasal drug pipeline, despite significant accumulated losses and a going concern warning from its auditors.

Summary

• Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing intranasal drugs for emergency medical conditions using its proprietary Powder-Based Intranasal (PBI) technology.
• The company is offering 1,250,000 ordinary shares in its initial public offering, with an anticipated price range of $8.00 to $10.00 per share, aiming to raise approximately $9.5 million in net proceeds.
• Primary focus is on NS002 (Intranasal Epinephrine) for severe allergies and anaphylaxis, which has completed Phase 2 studies, with plans for additional Phase 2 studies, a pivotal Phase 3 study, and an IND submission by Q3 2026.
• Development of NS001 (Intranasal Naloxone) for opioid overdose has been paused, with the company seeking partnering opportunities for its further development, despite having completed a pivotal Phase 3 study.
• As of December 31, 2024, the company reported an accumulated deficit of $12.7 million and cash and cash equivalents of $284 thousand, with auditors raising substantial doubt about its ability to continue as a going concern.
• The company expects its existing cash to fund operations only through September 2025 and will require substantial additional funding beyond the IPO proceeds to commercialize its product candidates.
• NS002 has shown immediate absorption and quicker, higher peak plasma Epinephrine levels compared to intramuscular (IM) Epinephrine injections in small pilot and Phase 2 studies, with statistical significance reached in Phase 2 after four minutes.
• NS001 demonstrated significantly faster absorption rates and higher plasma levels of Naloxone in the immediate critical period compared to Narcan in pilot and pivotal studies.
• The company's PBI technology offers advantages over liquid-based solutions, including potentially higher dispersion, larger absorption area, and enhanced consistency of delivered dose, along with superior stability for Epinephrine compared to liquid formulations.
• The company has identified material weaknesses in its internal control over financial reporting as of December 31, 2023, which have not yet been remediated.

Sentiment

Score: 4

Explanation: The company presents promising clinical data for its intranasal drug delivery technology and products, addressing significant unmet medical needs. However, it is in an early clinical stage with no approved products or revenue, faces substantial accumulated losses, has a going concern warning, and requires significant additional funding beyond the IPO. These financial and operational risks temper the positive sentiment from scientific progress.

Positives

• Proprietary Powder-Based Intranasal (PBI) technology shows promise for rapid and high drug absorption, potentially superior to liquid-based solutions.
• NS002 (Intranasal Epinephrine) pilot and Phase 2 studies demonstrated faster and quicker Epinephrine absorption compared to EpiPen, with statistically significant results in Phase 2.
• NS001 (Intranasal Naloxone) pivotal study consistently showed a significant advantage in the first 30 minutes after administration compared to Narcan, with higher plasma levels.
• The PBI Epinephrine formulation (NS002) demonstrated complete stability over a 2-year study, with 100% active Epinephrine, addressing known instability issues of liquid-based products.
• The company has successfully scaled up manufacturing and completed technology transfer for commercial quantities of its powder products, utilizing FDA and EMA approved vendors.
• A strong intellectual property position is maintained with multiple granted patents in the U.S., India, Japan, and Israel, covering dry powder formulations and Epinephrine delivery.
• The company has a clear strategic objective to develop and commercialize its PBI products, including seeking partnerships for advanced programs and exploring international regulatory approvals.
• The intranasal drug delivery market is substantial, estimated at $59 billion in 2022 and projected to grow to $93.7 billion by 2029, indicating significant market opportunity.

Negatives

• The company has incurred significant operating losses since inception, with an accumulated deficit of $12.7 million as of December 31, 2024.
• No revenues have been generated from existing product candidates to date, and profitability is uncertain even if regulatory approval is received.
• Current cash on hand ($284 thousand as of December 31, 2024) is insufficient to fund projected operating requirements beyond September 2025, raising substantial doubt about the company's ability to continue as a going concern.
• Clinical trials for product candidates have thus far involved relatively small patient populations, and observed effects in non-statistically powered trials may not be accurate.
• Development of NS001 (Intranasal Naloxone) has been paused, with the company seeking partnering opportunities, indicating a delay in its direct commercialization.
• The company relies on a limited number of suppliers, including Aptar as a sole supplier for its intranasal Unit Dose Spray (UDS) delivery system, posing supply chain risks.
• Material weaknesses in internal control over financial reporting were identified as of December 31, 2023, and have not yet been remediated, potentially affecting financial reporting accuracy and investor confidence.
• The pharmaceutical industry is intensely competitive, with major multinational companies having greater resources, brand recognition, and experience, potentially limiting the company's market penetration.
• The company has limited manufacturing experience and currently no manufacturing facilities for commercial scale production, relying on third-party manufacturers.
• As a foreign private issuer, the company intends to follow certain home country corporate governance practices instead of NYSE American requirements, which may result in less protection for U.S. investors.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to significant accumulated losses and insufficient current cash to fund operations.
• Uncertainty of obtaining regulatory approval for any product candidates, which is necessary for commercialization, and the lengthy, expensive, and uncertain nature of clinical drug development.
• Risk that preliminary clinical trial results may not be indicative of future trials, and that product candidates may lack sufficient efficacy or cause undesirable side effects not previously identified.
• Reliance on third-party manufacturers for Epinephrine and other formulations, and on a limited number of suppliers (e.g., Aptar for UDS), which could lead to delays, price increases, or unavailability.
• Potential for intellectual property rights to be limited, challenged, or unenforceable globally, especially for method-of-use patents which may not prevent off-label use by competitors.
• Intense competition in the pharmaceutical industry from companies with greater financial, human, and market resources, potentially limiting market acceptance and sales.
• Exposure to fluctuations in currency exchange rates, particularly between the U.S. dollar, New Israeli Shekels (NIS), and Euros, which could adversely affect results of operations.
• Potential for the termination or reduction of tax and other incentives provided by the Israeli government, increasing costs and taxes.
• Risk of being subject to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws, with potential for substantial penalties for non-compliance.
• Unstable market and economic conditions, including geopolitical conflicts in Israel and the Middle East, which could adversely affect operations, supply chains, and financial condition.
• Risk of product liability lawsuits, even with insurance, which could incur substantial liabilities, damage reputation, and divert management attention.
• Challenges in retaining key executives and attracting, retaining, and motivating qualified personnel, which are critical for future growth and success.
• Potential for the company to be characterized as a passive foreign investment company (PFIC) for U.S. tax purposes, leading to adverse U.S. income tax consequences for U.S. holders.
• Management team has limited experience managing a U.S. reporting company, potentially leading to difficulties in managing regulatory oversight and reporting obligations.
• Risk of security breaches, including cybersecurity incidents, which could disrupt operations, lead to data loss, and incur regulatory investigations or liabilities.

Future Outlook

The company intends to use the net proceeds from the IPO primarily for the development of its Intranasal Epinephrine program, including manufacturing scale-up and additional Phase 2 studies. It expects to require substantial additional funding beyond the IPO proceeds to complete research and development activities and commercialize its product candidates. The company plans to pursue partnering opportunities for the further development of Intranasal Naloxone and explore regulatory approval of its products outside the United States, particularly in the EU. Future expenses are expected to increase significantly as clinical trials progress and commercialization efforts begin.

Management Comments

• Our mission is to offer better protection to patients during acute, severe and life-threatening medical conditions by an effective, user-friendly and immediately active PBI specialized products.
• We are focused on developing NS002, an intranasal powder Epinephrine nasal spray for the treatment of type 1 severe allergies and anaphylaxis.
• We currently paused our work on NS001 and plan to pursue partnering opportunities for further development of NS001.
• We expect that we will need to raise substantial additional funding in the future.
• Our management will have broad discretion in the application of the net proceeds of this offering.

Industry Context

The company operates in the intensely competitive pharmaceutical industry, specifically targeting the intranasal drug delivery market for emergency medical conditions. This market was estimated at $59 billion globally in 2022 and is projected to reach $93.7 billion by 2029, with significant growth in the U.S. and Europe. The company aims to address unmet needs in anaphylaxis and opioid overdose treatment, where current solutions (like EpiPen and Narcan) face limitations such as needle fear, stability issues, and insufficient absorption rates in critical early minutes. The rise in anaphylactic episodes and the opioid epidemic (nearly 108,000 overdose deaths in the U.S. in 2022) highlight the urgent need for improved treatments. Competitors in the Epinephrine space include ARS Pharmaceuticals (Neffy), Bryn Pharma, Orexo AB, and Aquestive Therapeutics, while in Naloxone, competitors include Adapt Pharma (Narcan) and Hikma Pharmaceuticals (Kloxxado). The company's PBI technology seeks to differentiate by offering faster and higher drug absorption compared to liquid-based nasal sprays and IM injections.

Comparison to Industry Standards

• NS002 (Intranasal Epinephrine) demonstrated a median time to reach clinical plasma threshold (T100pg/ml) of 3.2 minutes (3.2 mg dosage under allergenic challenge), which was three times shorter compared to IM EpiPen (9 minutes).
• NS002's Tmax (time to maximum concentration) was shorter (10 minutes) compared to IM Epinephrine (14.6 minutes), and Cmax (maximum concentration) was higher (477 pg/ml vs 360 pg/ml) in Phase 2 studies, indicating faster and higher absorption.
• In comparison to other intranasal Epinephrine products in development: ARS Pharmaceuticals' Neffy had a Cmax of 341 pg/ml and Tmax of 30 minutes; Bryn Pharma's product achieved a Cmax of 429 pg/ml and Tmax of 20 minutes; Orexo AB's formulation showed a Cmax of 377 pg/ml and Tmax of 25 minutes; Aquestive Therapeutics' sublingual film had a Cmax of 497 pg/ml and Tmax of 15 minutes. Nasus Pharma's NS002 appears to show competitive or superior early absorption kinetics.
• NS001 (Intranasal Naloxone) pilot study showed a partial AUC0-4 minutes approximately 7-fold higher and partial AUC0-10 minutes approximately 4-fold higher compared to Narcan, indicating significantly faster absorption in the immediate critical period.
• NS001's pivotal study consistently showed a significant advantage in the first 30 minutes after administration compared to Narcan, with higher levels of Naloxone in the blood.
• The company's Epinephrine powder formulation (NS002) maintained 100% active form in stability studies, unlike commercial EpiPen devices which showed significant levels of inactive enantiomers, even before expiration, indicating superior stability.

Management Changes

Corporate Governance

Legal Proceedings

• In October 2022, the company received a termination notice from Aptar Group Inc. regarding an alleged breach of contractual obligations and outstanding payments of $1 million (including $450,000 in termination fees for the Naloxone SOW). The company contested the allegations, and while discussions occurred through February 2023, no resolution was reached. The company continues to purchase products from Aptar, and no further notices or claims have been received as of August 7, 2025. No legal proceeding is currently active between the parties.

Related Party Transactions

• The company has entered into services agreements with its executive officers, including Dan Teleman (CEO), Udi Gilboa (Executive Chairman, through TopNotch Ltd.), and Dr. Dalia Megiddo (CDO/CMO, through D.M. Medica Ltd.), detailing salaries, bonuses, and other benefits.
• Share options have been granted to officers and directors under the 2019 Incentive Option Plan.
• Loans were received from Dr. Ronnie Hershman (director/shareholder), Michael Gibber (shareholder), Mr. Udi Gilboa, and Dr. Dalia Megiddo, which were subsequently converted into Simple Agreements for Future Equity (SAFEs).
• A license agreement with Formulex Pharma Innovations Ltd. (owned by co-founders Mr. Gilboa, Dr. Megiddo, and Dr. Hershman) grants the company exclusive rights to Formulex's patent for dry powder compositions for intranasal delivery, with royalties capped at $100,000.
• A services agreement with Formulex provides chemical manufacturing and controls services for a fixed monthly cost of $5,000, with additional one-time development services provided in 2023.
• A subcontractor agreement with Formulex allows the company to retain Formulex's services for potential participation in tenders, with a maximum aggregate consideration of $800,000.
• Secretarial and administrative services are provided by Topnotch Consultancy (2009) Ltd. (owned by Mr. Udi Gilboa) for a monthly fee, which increased in April 2024.
• Office space is leased from Topnotch for a monthly fee.
• Co-founders and directors (Mr. Gilboa, Dr. Megiddo, Dr. Hershman) participated in the 2022, 2023, and 2024 SAFEs, which convert into Ordinary Shares upon certain events, including the IPO, at a discount.

Stakeholder Impact

• Shareholders: Will experience immediate dilution from the IPO, and existing shareholders' ownership interest will be diluted by future capital raises. The market price of shares may be highly volatile, and sales by existing shareholders after lock-up expiration could depress prices. The company's going concern status poses a significant risk to investment.
• Employees: Future growth depends on attracting and retaining qualified scientific, clinical, manufacturing, and sales personnel. Management changes and the small current employee base indicate significant expansion is needed, which could strain resources.
• Customers/Patients: Potential for new, user-friendly, and effective intranasal treatments for emergency medical conditions like anaphylaxis and opioid overdose, offering advantages over current injectable options. However, product availability depends on regulatory approvals and market acceptance.
• Suppliers/Creditors: Reliance on limited or single suppliers (e.g., Aptar) creates dependency. The company's financial position and going concern warning could impact its ability to meet obligations to creditors.
• Regulatory Authorities: The company's operations are subject to extensive and evolving regulations by agencies like the FDA and EMA. Compliance failures or changes in regulations could lead to delays, increased costs, or sanctions.

Next Steps

• Complete two additional Phase 2 studies for NS002 (Intranasal Epinephrine) to determine optimal second dose administration and carry-over effect, planned for Q4 2025.
• Submit an Investigational New Drug (IND) application for NS002 to the FDA, planned for Q3 2026.
• Initiate a pivotal Phase 3 clinical study for NS002, including a self-administration subsection, planned for Q3 2026.
• Initiate a pediatric study for NS002, with details to be agreed upon with the FDA, planned for Q4 2026.
• Perform stability testing, reliability studies, and usability studies for NS002 prior to marketing approval submission.
• Submit a New Drug Application (NDA) dossier for marketing approval of NS002 to the FDA, planned for Q2 2027.
• Pursue partnering opportunities for the further development of NS001 (Intranasal Naloxone).
• Explore regulatory approval of products outside the United States, including seeking scientific advice from European countries.
• Continue to develop additional pipeline programs for other indications (e.g., Intranasal Midazolam, Atropine, Ondansetron) using the PBI technology.
• Remediate identified material weaknesses in internal control over financial reporting.

Key Dates

Recommendation

While Nasus Pharma presents a compelling technology platform with promising early clinical data for its intranasal drug candidates, particularly NS002 for anaphylaxis, the company's financial position is highly precarious. The significant accumulated deficit of $12.7 million and the auditor's 'going concern' warning, coupled with limited cash reserves expected to last only until September 2025, indicate substantial financial risk. The IPO proceeds, while helpful, are explicitly stated as insufficient to complete all necessary development for commercialization, necessitating further capital raises. For a seasoned investor, the long-term potential of the PBI technology and the large target markets (anaphylaxis, opioid overdose) offer speculative upside. However, the immediate and severe financial challenges, the early stage of product development (especially NS002 still needing Phase 3), the pause on NS001's direct development, and the identified material weaknesses in internal controls warrant extreme caution. A 'hold' recommendation reflects a wait-and-see approach, acknowledging the high risk but also the potential for future value creation if the company successfully navigates its funding challenges, secures regulatory approvals, and addresses its internal control deficiencies. Investors should closely monitor financial stability, progress in clinical trials, and any strategic partnerships.

Keywords

Intranasal Drug Delivery, Epinephrine, Anaphylaxis, Naloxone, Opioid Overdose, Clinical Stage, Pharmaceutical, IPO, SEC Filing, Drug Development, Biotechnology, PBI Technology, NS002, NS001, FDA Approval, Clinical Trials, Risk Factors, Corporate Governance, Israel